/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

DiaMedica Therapeutics Inc Share Price Today: Live Updates & Key Insights

DiaMedica Therapeutics Inc share price today is $7.27, up -6.22%. The stock opened at $7.41 against the previous close of $7.72, with an intraday high of $7.565 and low of $7.22.

DiaMedica Therapeutics Inc Share Price Chart

style
pb-0

DiaMedica Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

DiaMedica Therapeutics Inc Share Price Performance

$7.27 -0.0622(-6.22%) DMAC at 13 Mar 2026 12:43 PM Biotechnology
Lowest Today 7.22
Highest Today 7.565
Today’s Open 7.41
Prev. Close 7.72
52 Week High 10.42
52 Week Low 3.19
Day’s Range: Low 7.22 High 7.565
52-Week Range: Low 3.19 High 10.42
1 day return -
1 Week return -6.65
1 month return -15.65
3 month return -16.96
6 month return +2.7
1 year return +27.11
3 year return +324.7
5 year return -24.55
10 year return -

DiaMedica Therapeutics Inc Institutional Holdings

Cooperman Leon G 3.88

BlackRock Inc 3.22

Millennium Management LLC 2.28

PARAGON Assoc & PARAGON Assoc II JV 1.68

iShares Russell 2000 ETF 1.57

Vanguard Group Inc 1.39

Geode Capital Management, LLC 1.37

Morgan Stanley - Brokerage Accounts 1.11

First Manhattan Co. LLC 0.97

State Street Corp 0.92

Bleichroeder LP 0.73

Northern Trust Corp 0.65

Fidelity Small Cap Index 0.64

Vanguard Institutional Extnd Mkt Idx Tr 0.62

iShares Russell 2000 Growth ETF 0.54

Advisor Group Holdings, Inc. 0.47

LPL Financial Corp 0.39

State St Russell Sm/Mid Cp® Indx SL Cl I 0.37

Fidelity Extended Market Index 0.31

Vanguard Russell 2000 ETF 0.31

CI Private Wealth LLC 0.27

IMC US Ultra Micro Cap 0.21

Nuveen, LLC 0.21

State St Russell Sm Cap® Indx SL Cl I 0.20

Wellington Management Company LLP 0.20

MEMBERS WEALTH LLC 0.19

Charles Schwab Investment Management Inc 0.19

Kalehua Capital Management LLC 0.18

The Informed Momentum Company (formerly EAM Investors) 0.18

iShares Micro-Cap ETF 0.17

Blackrock Extended Mkt Fund CF 0.17

Schwab Small Cap Index 0.16

Extended Equity Market Fund K 0.15

NT R2000 Index Fund - NL 0.14

CREF Total Global Stock Account R3 0.14

Jacob Discovery Fd Instl 0.13

Fidelity Total Market Index 0.12

NT R2000 Index Fund - DC - NL - 3 0.12

iShares Russell 2000 Small-Cap Idx Instl 0.11

Alger LIfe Sciences Innovation Composite 0.11

DiaMedica Therapeutics Inc Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

DiaMedica Therapeutics Inc Fundamentals

Market Cap 402.04 M

PB Ratio 7.7881

PE Ratio 0.0

Enterprise Value 346.99 M

Total Assets 46.35 M

Volume 392883

DiaMedica Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-17971000 -18.0M, FY22:-13676000 -13.7M, FY21:-13592000 -13.6M, FY20:-12292000 -12.3M, FY19:-10649000 -10.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-18000 -0.0M, Q2/2025:-3000 -0.0M, Q1/2025:-11000 -0.0M, Q3/2024:-6883000 -6.9M, Q2/2024:-10000 -0.0M

Quarterly Net worth Q3/2025:-8620000 -8.6M, Q2/2025:-7699000 -7.7M, Q1/2025:-7707000 -7.7M, Q3/2024:-6274000 -6.3M, Q2/2024:-5119000 -5.1M

About DiaMedica Therapeutics Inc & investment objective

Company Information DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Organisation Biotechnology

Employees 27

Industry Biotechnology

CEO Mr. Dietrich John Pauls MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow